Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
NCT ID: NCT00445744
Last Updated: 2018-01-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2006-12-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
NCT00049634
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00004896
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
NCT01056614
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT02861417
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To estimate the incidence of hepatotoxicity with a conditioning regimen of CY (cyclophosphamide)/tBU (busulfan) in patients receiving hematopoietic cell transplant (HCT).
SECONDARY OBJECTIVES:
I. To determine overall and non-relapse mortality at day +200 after HCT.
II. To determine the peak bilirubin levels through day +20 after HCT.
III. To determine the incidence of pulmonary toxicity in the form of idiopathic pulmonary syndrome (IPS).
IV. To determine the rate of graft failure.
V. To determine the time to engraftment.
VI. To determine the rate of relapse.
VII. To determine the incidence and severity of graft-versus-host disease (GVHD).
VIII. To evaluate the pharmacokinetics/dynamics of BU and CY.
X. To evaluate the pharmacogenomics of response, toxicity and pharmacokinetics of CY/tBU.
OUTLINE:
CONDITIONING REGIMEN: Patients receive cyclophosphamide intravenously (IV) on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or orally (PO) twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
After completion of study treatment, patients are followed periodically.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (cyclophosphamide, busulfan, transplant)
CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
cyclophosphamide
Given IV
busulfan
Given IV
tacrolimus
Given IV or PO
methotrexate
Given IV
cytogenetic analysis
Correlative studies
flow cytometry
Correlative studies
pharmacological study
Correlative studies
pharmacogenomic studies
Correlative studies
peripheral blood stem cell transplantation
Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation
Undergo allogeneic transplantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cyclophosphamide
Given IV
busulfan
Given IV
tacrolimus
Given IV or PO
methotrexate
Given IV
cytogenetic analysis
Correlative studies
flow cytometry
Correlative studies
pharmacological study
Correlative studies
pharmacogenomic studies
Correlative studies
peripheral blood stem cell transplantation
Undergo PBPC transplantation
allogeneic hematopoietic stem cell transplantation
Undergo allogeneic transplantation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Myelofibrosis developing with polycythemia vera or essential thrombocythemia
* Acute myeloid leukemia with or without antecedent hematologic disorder, at any disease stage (complete remission, minimal residual disease, or relapsed leukemia)
* Myelodysplastic syndrome of any World Health Organization (WHO) or French-American-British (FAB) category, at any disease stage
* Less than 61 years of age if transplanted from an unrelated donor, or less than 66 years of age if transplanted from a related donor
* Receiving unmanipulated peripheral blood stem cells from an human leukocyte antigen (HLA)-identical or 1-allele-mismatched related or unrelated donor, or receiving G-CSF-stimulated bone marrow if co-enrolled on Fred Hutchinson Cancer Research Center (FHCRC) protocol 2250
* With a Karnofsky Performance score of \> 70% at the time of pre-transplant evaluation
* Able to give informed consent (if \>= 18 years of age), or with a legal guardian capable of giving consent (if \< 18 years of age)
* DONOR: HLA-identical or 1-allele-mismatched related or unrelated donors (by high resolution typing)
* DONOR: Undergoing peripheral blood stem cell harvest or G-CSF-stimulated bone marrow harvest (bone marrow permitted only as part of FHCRC protocol 2250)
* DONOR: In good general health, with a Karnofsky performance score of \> 80%
* DONOR: Able to give informed consent (if \>= 18 years of age), or with a legal guardian able to give informed consent (if \< 18 years of age and donating for a related transplant)
Exclusion Criteria
* With human immunodeficiency virus (HIV) positivity or active infectious hepatitis
* Receiving a medication known to strongly inhibit enzymes in the CYP450 pathway, and which, in the judgment of the consenting provider, cannot be safely discontinued for the duration of conditioning
* Whose life expectancy is severely limited by diseases other than the hematologic disorder for which they are undergoing HCT (HCT-comorbidity index \[CI\] \> 3)
* Women who are pregnant or lactating
* With known hypersensitivity to BU or CY
* With hepatic dysfunction as evidenced by total bilirubin or AST \> 2x the upper limit of normal, or evidence of synthetic dysfunction or cirrhosis
* With impaired renal function, as evidenced by creatinine clearance \< 50% of expected, creatinine \> 2x the upper limit of normal, or dialysis dependence
* With impaired pulmonary function, as evidenced by pO2 \< 70 mm Hg and diffusing capacity of carbon monoxide (DLCO) \< 70% predicted or by pO2 \< 80 mm Hg and DLCO \< 60%, or receiving continuous supplementary oxygen
* With impaired cardiac function, as evidenced by ejection fraction \< 35% or active coronary artery disease
* Unable to give informed consent
* DONOR: Deemed unable to undergo stem cell collection, for any reason
* DONOR: HIV-positive, or hepatitis B or C antigen-positive
* DONOR: Women with a positive pregnancy test
* DONOR: Unable to give informed consent (if \>= 18 years of age), or without a legal guardian able to give informed consent (if \<18 years of age)
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Cancer Institute (NCI)
NIH
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joachim Deeg
Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Rezvani
Role: PRINCIPAL_INVESTIGATOR
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2010-00270
Identifier Type: REGISTRY
Identifier Source: secondary_id
2130.00
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.